ClinicalTrials.gg
CompletedNCT00440947Updated Mar 22, 2012Results posted

Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection

A Phase 3 interventional study of Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r) and Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) in Infection, Human Immunodeficiency Virus I and HIV Infection, sponsored by ViiV Healthcare. Completed at 72 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-22.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
515
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies testing abacavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Abacavir · HIV Infections.

Enrollment
4th of 50
515 · median 78
Started
2007
with 2 others
Phase 3
16 of 57
1 open now
Registered
46th of 57
by date
Lead sponsor
3 of 57
ViiV Healthcare

Among the 57 studies testing abacavir in HIV Infections, this one is the 4th largest by enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2007, is one of 16 in phase 3, and was the 46th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 57 studies testing abacavir in HIV Infections is open now. Recruiting first, the newest first:

About abacavir

Abacavir: first FDA approval 1998 (ZIAGEN), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing abacavir in HIV Infections, or all of them as a file.
02

Study summary

This study was designed to test the efficacy, safety, tolerability and durability of the antiviral response between atazanavir (ATV) + ritonavir (/r) + abacavir/lamivudine(ABC/3TC) Fixed dose combination (FDC) each administered once daily (QD) for 36 weeks followed by randomization to either a simplification regimen of ATV or continuation of ATV +/r for an additional 48 weeks, each in combination with ABC/3TC in antiretroviral (ART)-naive, HIV-1 infected, HLA-B*5701 negative subjects.

All subjects who complete the 84-week study will be eligible to enter the treatment extension phase and continue for an additional 60 weeks. The purpose of this extension is to obtain longer term treatment data in subjects who have completed the 84-week study.

Read the detailed description

Safety and Efficacy of an Initial Regimen of Atazanavir (ATV) + Ritonavir (/r) + the Abacavir/Lamivudine Fixed-Dose Combination Tablet (ABC/3TC FDC) for 36 weeks followed by Simplification to Atazanavir with ABC/3TC FDC or Maintenance of the Initial Regimen for an Additional 48 weeks in Antiretroviral-Naive HIV-1 Infected HLA-B*5701 Negative Subjects followed by an Optional 60-Week Treatment Extension Phase

03

Conditions studied

  • Infection, Human Immunodeficiency Virus I
  • HIV Infection

Browse trials for

Keywords

  • NORVIR
  • ARIES
  • EPZICOM
  • REYATAZ
  • HIV
  • simplification
  • Antiretroviral-naive
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

This study's enrollment of 515 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥ 18 years of age and has documented evidence of -1 infection. (A female is eligible to enter and participate in this study if she is of: non , child bearing potential with a negative pregnancy test and agrees to approved methods, or agreement for complete abstinence.)
  • Subject is antiretroviral-naïve (defined as having ≤14 days of prior therapy with any NRTI and no prior therapy with either a PI or NNRTI).
  • Subject has plasma HIV-1 RNA ≥ 1,000 copies/mL by Roche COBAS AMPLICOR™ (Version 1.5) method at screening (if no other documentation of HIV infection is available, a positive result here may serve as documentation of HIV infection for this study).
  • Subject is willing and able to understand and provide written prior to participation in this study.

Exclusion criteria

Exclusion criteria:

  • Subject is HLA-B*5701 positive.
  • Subject testing positive for or both Hepatitis B and at screening (+ HbsAg)
  • Genotyping results performed at the screening indicate that the subject has any of the following mutations at the reverse transcriptase (RT) enzyme: K65R, L74V, or Y115F, or a combination of two or more thymidine analog mutations (M41L, D67N, K70R, K219Q or E) that include changes at either L210 or T215, or ≥ 3 of the following protease mutations associated with atazanavir resistance: D30, V32, M36, M46, I47, G48, I50, I54, A71, G73, V77, V82, I84, N88, and L90.
  • Women who are pregnant or breastfeeding.
  • Subject has an active or acute CDC Clinical Category C event at screening. Treatment for the acute event must have been completed at least 30 days prior to screening.
  • Subject is, in the opinion of the investigator, unable to complete the 84-week dosing period and protocol evaluations and assessments.
  • Subject has ongoing pancreatitis or clinically relevant hepatitis at screening.
  • Presence of a newly diagnosed -related opportunistic infection or any medical condition requiring acute therapy at the time of enrollment.
  • Subject suffers from a serious medical condition, such as diabetes, congestive heart failure, cardiomyopathy or other cardiac dysfunction (including known, clinically significant cardiac conduction system disease, severe first degree atrioventricular block [PR interval > 0.26 seconds], second or third-degree atrioventricular block), which in the opinion of the investigator would compromise the safety of the subject.
  • Subject has pre-existing mental, physical, or substance abuse disorder, which in the opinion of the investigator would interfere with the subject's ability to comply with the dosing schedule and protocol evaluations and assessments.
  • Subject has a history of inflammatory bowel disease or , intestinal ischemia, malabsorption, or other gastrointestinal dysfunction, which may interfere with drug absorption or render the subject unable to take oral medication.
  • Subject requires treatment with foscarnet, hydroxyurea or other agents with documented activity against HIV-1 in vitro within 28 days of study administration.
  • Subject requires treatment with immunomodulating agents (such as systemic , interleukins, vaccines, or interferons) within 28 days prior to screening, or subject had received an HIV-1 immunotherapeutic vaccine within 90 days prior to screening. Subjects using inhaled corticosteroids are eligible for enrollment.
  • \<50 mL/min via the Cockroft-Gault method [Cockroft, 1976].
  • Active alcohol or substance use sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis or chemical hepatitis.
  • to any component of the study drugs.
  • (AST) or alanine aminotransferase (ALT) >5 times the (ULN).
  • Total > 1.5 times the upper limit of normal (ULN).
  • Subject has any acute laboratory abnormality at screening, which, in the opinion of the investigator, would preclude the subject's participation in the study of an compound. Any grade 4 laboratory abnormality would exclude a subject from study participation.
  • Subject requires treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days prior to screening, or has an anticipated need for these agents within the study period.
  • Enrolled in one or more investigational drug protocols, which may have impacted HIV-1 RNA suppression.
  • Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.
  • Subjects requiring concomitant administration of proton pump inhibitors.
  • Subjects who require treatment with the prohibited medications within 28 days of commencement of investigational product, or an anticipated need during the study.

Eligibility Criteria for Treatment Extension Phase:

-Subjects will be eligible to continue in the treatment extension phase (Weeks 84 to 144) if they have successfully completed the 84-week study.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
515 participants (actual)

Study arms

  • Other
    Simplification

    Atazanavir (ATV) 400 mg QD + abacavir (ABC) 600 mg/lamivudine (3TC) 300 mg fixed dose combination (FDC) QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.

    Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)

  • Other
    Continuation

    Atazanavir (ATV) 300 mg QD + ritonavir (/r) 100 mg QD + abacavir (ABC) 600mg/lamivuidine (3TC )300 mg FDC QD for 48 weeks followed by optional treatment extension for 60 weeks on the same regimen.

    Drug: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)

Interventions

  • DrugAbacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)

    Drug pages: Abacavir · Lamivudine · Atazanavir · Ritonavir

    Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen

  • DrugAbacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)

    Drug pages: Abacavir · Lamivudine · Atazanavir

    Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen

07

What researchers measure

Primary outcomes

  1. Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c) /Milliliter (ml) at the Week 84 Visit

    The percentage of PAR with HIV-1 RNA virus \<50 c/ml determined from a blood sample drawn at Week 84 was tabulated by treatment arm with stratification by baseline HIV-1 RNA (\<100,000 c/ml and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed viral load \<50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA \<50 c/ml, prematurely discontinued study or study medication for any reason, had confirmed rebound to at least 50 c/ml, or had an unconfirmed HIV RNA of at least 50 c/ml at last visit.

    Time frame: Week 84

Secondary outcomes

  1. Mean Age at Baseline of Participants Randomized to Treatment for the 48-Week Randomized Phase

    The mean age of participants randomized to treatment in the Randomized Phase was calculated at Baseline.

    Time frame: Baseline of Randomized Phase

  2. Percentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 36 Visit

    The percentage of PAR with HIV-1 RNA virus \<50 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed viral load \<50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA \<50 c/ml, prematurely discontinued (DC) study or study medication (any reason), had confirmed rebound to \>=50 c/ml, or had an unconfirmed HIV RNA \>=50 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study medication DC were failures.

    Time frame: Week 36

  3. Percentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 84 Visit

    A blood sample was drawn to determine the amount of HIV-1 RNA virus in c/ml at Week 84. The percentage of participants with HIV-1 RNA \<50 c/ml at Week 84 was tabulated. The secondary analysis methods were: Observed (Obs; uses all visits with data in the analysis period), and missing/discontinuation=failure (M/D=F) analyses. M/D=F: participants with missing data or data collected after study medication DC were considered failures.

    Time frame: Week 84

  4. Percentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 144 Visit

    Percentage of PAR with HIV-1 RNA \<50 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA \<50 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<50 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=50 c/ml, or had an unconfirmed HIV RNA \>=50 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.

    Time frame: Week 144

  5. Percentage of Participants Who Achieved Plasma HIV-1 RNA <400 c/ml at the Week 36 Visit

    The percentage of PAR with HIV-1 RNA virus \<400 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA \<400 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med; any reason), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.

    Time frame: Week 36

  6. Percentage of Participants Who Achieved HIV-1 RNA <400 c/ml at the Week 84 Visit

    Percentage of PAR with HIV-1 RNA \<400 c/ml at Week 84 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA \<400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.

    Time frame: Week 84

  7. Percentage of Participants Who Achieved HIV-1 RNA <400 c/ml at the Week 144 Visit

    Percentage of PAR with HIV-1 RNA \<400 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA \<400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.

    Time frame: Week 144

  8. Number of Participants Who Met the Protocol-defined Virologic Failure (PDVF) Criteria at Week 36

    The number of participants that failed to respond to therapy through 36 weeks on treatment, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.

    Time frame: Week 36

  9. Number of Participants Who Met the PDVF Criteria at Week 84

    The number of participants that failed to respond to therapy from the time of treatment randomization through Week 84, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.

    Time frame: Week 84

  10. Number of Participants Who Met the PDVF Criteria at Week 144

    The number of participants enrolled in the extension phase that failed to respond to therapy from Week 84 through Week 144, based on the protocol definition of virologic failure (PDVF) was tabulated,. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.

    Time frame: Week 144

  11. Change From Baseline in HIV-1 RNA at Week 36

    Change from baseline was calculated as the Week 36 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.

    Time frame: Baseline and Week 36

  12. Change From Baseline in HIV-1 RNA at Week 84

    Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.

    Time frame: Baseline and Week 84

  13. Change From Baseline in HIV-1 RNA at Week 144

    Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.

    Time frame: Baseline and Week 144

  14. Change From Baseline in CD4+ Cell Count at Week 36

    Blood was drawn to analyze for CD4+ cell count. A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 36 value minus the baseline value.

    Time frame: Baseline and Week 36

  15. Change From Baseline in CD4+ Cell Count at Week 84

    A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.

    Time frame: Baseline and Week 84

  16. Change From Baseline in CD4+ Cell Count at Week 144

    A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.

    Time frame: Baseline and Week 144

  17. Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Baseline Through Week 36

    A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New resistance-associated mutations (defined by the International AIDS Society-USA guidelines) that developed at the time of failure were tabulated by drug class. PAR, participants; VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

    Time frame: Baseline through Week 36

  18. Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Randomization at Week 36 Through Week 84

    A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

    Time frame: Randomization at Week 36 through Week 84

  19. Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Week 84 Through Week 144

    A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

    Time frame: Week 84 through Week 144

  20. Number of Confirmed Virologic Failure Participants From Baseline Through Week 36 With Treatment-emergent Reductions in Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir

    A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.

    Time frame: Baseline through Week 36

  21. Number of Confirmed Virologic Failure Participants From Randomization at Week 36 Through Week 84 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir

    A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.

    Time frame: Randomization at Week 36 through Week 84

  22. Number of Confirmed Virologic Failure Participants From Week 84 Through Week 144 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir

    A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.

    Time frame: Week 84 through Week 144

  23. Mean Percent Compliance at Week 36

    Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.

    Time frame: Week 36

  24. Mean Percent Compliance at Week 84

    Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.

    Time frame: Week 84

  25. Mean Percent Compliance at Week 144

    Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.

    Time frame: Week 144

08

Results

Posted Aug 17, 2011

Participant flow

Participants (PAR) were recruited at 66 centers in the United States of America and Canada. HIV-RNA, human immunodeficiency virus-ribonucleic acid; ml, milliliters.

36-Week Induction Phase
Participant flow — 36-Week Induction Phase
MilestoneABC/3TC + ATV/r: Induction PhaseABC/3TC + ATV: Randomization PhaseABC/3TC + ATV/r: Randomization PhaseABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
Started5150000
Completed4420000
Not completed730000
Withdrew: Adverse event160000
Withdrew: Insufficient viral load response110000
Withdrew: Protocol-defined virologic failure50000
Withdrew: Non-compliance100000
Withdrew: Lost to follow-up160000
Withdrew: Withdrawal by subject70000
Withdrew: Kaposi lesions requiring chemotherapy10000
Withdrew: Took exclusionary medications10000
Withdrew: Genotype had exclusionary mutations10000
Withdrew: Fleeing police; outstanding warrants10000
Withdrew: Incarceration30000
Withdrew: Pregnancy10000
48-Week Randomization Phase
Participant flow — 48-Week Randomization Phase
MilestoneABC/3TC + ATV/r: Induction PhaseABC/3TC + ATV: Randomization PhaseABC/3TC + ATV/r: Randomization PhaseABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
Started021020900
Completed019418500
Not completed0162400
Withdrew: Adverse event02500
Withdrew: Protocol-defined virologic failure01100
Withdrew: Non-compliance03400
Withdrew: Lost to follow-up02800
Withdrew: Protocol violation00100
Withdrew: Withdrawal by subject02400
Withdrew: Pregnancy00100
Withdrew: Incarceration03000
Withdrew: Trying to get pregnant01000
Withdrew: Physician decision02000
Optional 60-Week Extension Phase
Participant flow — Optional 60-Week Extension Phase
MilestoneABC/3TC + ATV/r: Induction PhaseABC/3TC + ATV: Randomization PhaseABC/3TC + ATV/r: Randomization PhaseABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
Started000189180
Completed000160154
Not completed0002926
Withdrew: Adverse event00013
Withdrew: Insufficient viral load response00011
Withdrew: Protocol-defined virologic failure00032
Withdrew: Non-compliance00011
Withdrew: Lost to follow-up00099
Withdrew: Protocol violation00010
Withdrew: Withdrawal by subject00043
Withdrew: Pregnancy00030
Withdrew: Participant moved00011
Withdrew: Sponsor request00011
Withdrew: Sponsor terminated site00033
Withdrew: Other00010
Withdrew: Physician decision00001
Withdrew: Participant remained in cuba00001

Outcome measures

PrimaryPercentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c) /Milliliter (ml) at the Week 84 Visit

The percentage of PAR with HIV-1 RNA virus \<50 c/ml determined from a blood sample drawn at Week 84 was tabulated by treatment arm with stratification by baseline HIV-1 RNA (\<100,000 c/ml and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed viral load \<50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA \<50 c/ml, prematurely discontinued study or study medication for any reason, had confirmed rebound to at least 50 c/ml, or had an unconfirmed HIV RNA of at least 50 c/ml at last visit.

Time frame:
Week 84
Reported as:
Number · percentage of participants
Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c) /Milliliter (ml) at the Week 84 Visit
percentage of participantsABC/3TC + ATV: Randomized PhaseABC/3TC + ATV/r: Randomized Phase
Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c) /Milliliter (ml) at the Week 84 Visit8681
Statistical analysis
  • ABC/3TC + ATV: Randomized Phase vs ABC/3TC + ATV/r: Randomized Phase · Cochran-Mantel-Haenszel · p = 0.140 · Risk difference (rd): 5.4 · 95% CI -1.8 to 12.5p-value was obtained from Cochran-Mantel-Haenszel stratified by baseline HIV-1 RNA (\<100000/\>=100000)
SecondaryMean Age at Baseline of Participants Randomized to Treatment for the 48-Week Randomized Phase

The mean age of participants randomized to treatment in the Randomized Phase was calculated at Baseline.

Time frame:
Baseline of Randomized Phase
Reported as:
Mean · years
Mean Age at Baseline of Participants Randomized to Treatment for the 48-Week Randomized Phase
yearsABC/3TC + ATV: Randomized PhaseABC/3TC + ATV/r: Randomized Phase
Mean Age at Baseline of Participants Randomized to Treatment for the 48-Week Randomized Phase37.5 ± 10.2339.7 ± 9.71
SecondaryPercentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 36 Visit

The percentage of PAR with HIV-1 RNA virus \<50 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed viral load \<50 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved confirmed HIV RNA \<50 c/ml, prematurely discontinued (DC) study or study medication (any reason), had confirmed rebound to \>=50 c/ml, or had an unconfirmed HIV RNA \>=50 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study medication DC were failures.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 36 Visit
percentage of participantsABC/3TC + ATV/r: Induction Phase
TLOVR80
Obs88
M/D=F77
SecondaryPercentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 84 Visit

A blood sample was drawn to determine the amount of HIV-1 RNA virus in c/ml at Week 84. The percentage of participants with HIV-1 RNA \<50 c/ml at Week 84 was tabulated. The secondary analysis methods were: Observed (Obs; uses all visits with data in the analysis period), and missing/discontinuation=failure (M/D=F) analyses. M/D=F: participants with missing data or data collected after study medication DC were considered failures.

Time frame:
Week 84
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 84 Visit
percentage of participantsABC/3TC + ATV: Randomized PhaseABC/3TC + ATV/r: Randomized Phase
Obs9292
M/D=F8582
SecondaryPercentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 144 Visit

Percentage of PAR with HIV-1 RNA \<50 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA \<50 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<50 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=50 c/ml, or had an unconfirmed HIV RNA \>=50 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.

Time frame:
Week 144
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Plasma HIV-1 RNA <50 c/ml at the Week 144 Visit
percentage of participantsABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
TLOVR7773
Obs9592
M/D=F8078
SecondaryPercentage of Participants Who Achieved Plasma HIV-1 RNA <400 c/ml at the Week 36 Visit

The percentage of PAR with HIV-1 RNA virus \<400 c/ml from a Week 36 blood sample was tabulated. Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV RNA \<400 c/ml who had not met any non-responder criterion. Non-responders were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med; any reason), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. ITT-E observed analysis (Obs): all observed data. ITT-E M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.

Time frame:
Week 36
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Plasma HIV-1 RNA <400 c/ml at the Week 36 Visit
percentage of participantsABC/3TC + ATV/r: Induction Phase
TLOVR82
Obs98
M/D=F84
SecondaryPercentage of Participants Who Achieved HIV-1 RNA <400 c/ml at the Week 84 Visit

Percentage of PAR with HIV-1 RNA \<400 c/ml at Week 84 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA \<400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.

Time frame:
Week 84
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA <400 c/ml at the Week 84 Visit
percentage of participantsABC/3TC + ATV: Randomized PhaseABC/3TC + ATV/r: Randomized Phase
TLOVR9286
Obs9998
M/D=F9287
SecondaryPercentage of Participants Who Achieved HIV-1 RNA <400 c/ml at the Week 144 Visit

Percentage of PAR with HIV-1 RNA \<400 c/ml at Week 144 was tabulated; stratified by baseline HIV-1 RNA (\<100,000 and \>=100,000 c/ml). Per TLOVR algorithm, responders were PAR with confirmed (CF) HIV-RNA \<400 c/ml who had not met any non-responder (NR) criterion. NR were PAR who never achieved CF HIV RNA \<400 c/ml, prematurely discontinued (DC) study or study medication (Med), had CF rebound to \>=400 c/ml, or had an unconfirmed HIV RNA \>=400 c/ml at last visit. Observed analysis (Obs): all observed data. M/D=F analysis: PAR with missing data/data collected after study Med DC were failures.

Time frame:
Week 144
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA <400 c/ml at the Week 144 Visit
percentage of participantsABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
TLOVR8480
Obs9997
M/D=F8482
SecondaryNumber of Participants Who Met the Protocol-defined Virologic Failure (PDVF) Criteria at Week 36

The number of participants that failed to respond to therapy through 36 weeks on treatment, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.

Time frame:
Week 36
Reported as:
Number · participants
Number of Participants Who Met the Protocol-defined Virologic Failure (PDVF) Criteria at Week 36
participantsABC/3TC + ATV/r: Induction Phase
Protocol-defined virologic failure15
Failure to achieve <400 c/ml by Week 305
Confirmed rebound after achieving <400 c/ml10
SecondaryNumber of Participants Who Met the PDVF Criteria at Week 84

The number of participants that failed to respond to therapy from the time of treatment randomization through Week 84, based on the protocol definition of virologic failure (PDVF), was tabulated. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.

Time frame:
Week 84
Reported as:
Number · participants
Number of Participants Who Met the PDVF Criteria at Week 84
participantsABC/3TC + ATV: Randomized PhaseABC/3TC + ATV/r: Randomized Phase
Protocol-defined virologic failure17
Confirmed rebound after achieving <400 c/ml17
SecondaryNumber of Participants Who Met the PDVF Criteria at Week 144

The number of participants enrolled in the extension phase that failed to respond to therapy from Week 84 through Week 144, based on the protocol definition of virologic failure (PDVF) was tabulated,. PDVF was defined as (a) failure to achieve plasma HIV-1 RNA \<400 c/ml by Week 30 or (b) confirmed HIV-1 RNA rebound \>=400 c/ml after achieving HIV-1 \<400 c/ml.

Time frame:
Week 144
Reported as:
Number · participants
Number of Participants Who Met the PDVF Criteria at Week 144
participantsABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
Protocol-defined virologic failure56
Confirmed rebound after achieving <400 c/ml56
SecondaryChange From Baseline in HIV-1 RNA at Week 36

Change from baseline was calculated as the Week 36 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.

Time frame:
Baseline and Week 36
Reported as:
Mean · log10 c/ml
Change From Baseline in HIV-1 RNA at Week 36
log10 c/mlABC/3TC + ATV/r: Induction Phase
Change From Baseline in HIV-1 RNA at Week 36-3.241 ± 0.775
SecondaryChange From Baseline in HIV-1 RNA at Week 84

Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.

Time frame:
Baseline and Week 84
Reported as:
Mean · log10 c/ml
Change From Baseline in HIV-1 RNA at Week 84
log10 c/mlABC/3TC + ATV: Randomized PhaseABC/3TC + ATV/r: Randomized Phase
Change From Baseline in HIV-1 RNA at Week 84-3.261 ± 0.681-3.270 ± 0.698
SecondaryChange From Baseline in HIV-1 RNA at Week 144

Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for plasma HIV viral load.

Time frame:
Baseline and Week 144
Reported as:
Mean · log10 c/ml
Change From Baseline in HIV-1 RNA at Week 144
log10 c/mlABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
Change From Baseline in HIV-1 RNA at Week 144-3.291 ± 0.675-3.239 ± 0.835
SecondaryChange From Baseline in CD4+ Cell Count at Week 36

Blood was drawn to analyze for CD4+ cell count. A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 36 value minus the baseline value.

Time frame:
Baseline and Week 36
Reported as:
Mean · cells/millimeters cubed (mm^3)
Change From Baseline in CD4+ Cell Count at Week 36
cells/millimeters cubed (mm^3)ABC/3TC + ATV/r: Induction Phase
Change From Baseline in CD4+ Cell Count at Week 36185.4 ± 121.84
SecondaryChange From Baseline in CD4+ Cell Count at Week 84

A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 84 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.

Time frame:
Baseline and Week 84
Reported as:
Mean · cells/millimeters cubed (mm^3)
Change From Baseline in CD4+ Cell Count at Week 84
cells/millimeters cubed (mm^3)ABC/3TC + ATV: Randomized PhaseABC/3TC + ATV/r: Randomized Phase
Change From Baseline in CD4+ Cell Count at Week 84265.7 ± 157.65282.9 ± 150.49
SecondaryChange From Baseline in CD4+ Cell Count at Week 144

A CD4+ cell is a T lymphocyte that carries the CD4 antigen. Immunologic response was assessed by CD4+ counts. Change from baseline was calculated as the Week 144 value minus the baseline value. Blood was drawn to analyze for CD4+ cell count.

Time frame:
Baseline and Week 144
Reported as:
Mean · cells/millimeters cubed (mm^3)
Change From Baseline in CD4+ Cell Count at Week 144
cells/millimeters cubed (mm^3)ABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
Change From Baseline in CD4+ Cell Count at Week 144317.7 ± 161.98325.1 ± 178.29
SecondaryNumber of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Baseline Through Week 36

A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New resistance-associated mutations (defined by the International AIDS Society-USA guidelines) that developed at the time of failure were tabulated by drug class. PAR, participants; VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Time frame:
Baseline through Week 36
Reported as:
Number · participants
Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Baseline Through Week 36
participantsABC/3TC + ATV/r: Induction Phase
PAR with paired genotypes at baseline and VF15
PAR with treatment-emergent mutations6
PAR with NRTI mutations4
PAR with NNRTI mutations1
PAR with major PI mutations0
PAR with minor PI mutations2
SecondaryNumber of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Randomization at Week 36 Through Week 84

A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Time frame:
Randomization at Week 36 through Week 84
Reported as:
Number · participants
Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Randomization at Week 36 Through Week 84
participantsABC/3TC + ATV: Randomized PhaseABC/3TC + ATV/r: Randomized Phase
PAR with paired genotypes at baseline and VF17
PAR with treatment-emergent mutations12
PAR with NRTI mutations10
PAR with NNRTI mutations00
PAR with major PI mutations00
PAR with minor PI mutations02
SecondaryNumber of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Week 84 Through Week 144

A blood sample was drawn for participants failing to respond to therapy, and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New International AIDs Society-USA defined resistance mutations that developed at the time of failure were tabulated by drug class. VF, virologic failure; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.

Time frame:
Week 84 through Week 144
Reported as:
Number · participants
Number of Confirmed Virologic Failure Participants With Treatment-emergent HIV Genotypic Resistance in Reverse Transcriptase and Protease From Week 84 Through Week 144
participantsABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
PAR with paired genotypes at baseline and VF55
PAR with treatment-emergent mutations21
PAR with NRTI mutations01
PAR with NNRTI mutations00
PAR with major PI mutations01
PAR with minor PI mutations21
SecondaryNumber of Confirmed Virologic Failure Participants From Baseline Through Week 36 With Treatment-emergent Reductions in Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir

A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.

Time frame:
Baseline through Week 36
Reported as:
Number · participants
Number of Confirmed Virologic Failure Participants From Baseline Through Week 36 With Treatment-emergent Reductions in Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir
participantsABC/3TC + ATV/r: Induction Phase
PAR with reduced abacavir susceptibility0
PAR with reduced lamivudine susceptibility1
PAR with reduced atazanavir susceptibility0
PAR with reduced ritonavir susceptibility0
SecondaryNumber of Confirmed Virologic Failure Participants From Randomization at Week 36 Through Week 84 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir

A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.

Time frame:
Randomization at Week 36 through Week 84
Reported as:
Number · participants
Number of Confirmed Virologic Failure Participants From Randomization at Week 36 Through Week 84 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir
participantsABC/3TC + ATV: Randomized PhaseABC/3TC + ATV/r: Randomized Phase
PAR with reduced abacavir susceptibility00
PAR with reduced lamivudine susceptibility10
PAR with reduced atazanavir susceptibility00
PAR with reduced ritonavir susceptibility00
SecondaryNumber of Confirmed Virologic Failure Participants From Week 84 Through Week 144 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir

A blood sample was drawn for participants failing to respond to therapy, and changes in drug susceptibility for HIV isolated from the participants for each drug used in the study were assessed. For each participant, the changes in drug susceptibility detected by phenotypic assay in virus from the sample collected at the time of failure was compared with drug susceptibility in the virus from the blood sample at baseline. PAR, participant.

Time frame:
Week 84 through Week 144
Reported as:
Number · participants
Number of Confirmed Virologic Failure Participants From Week 84 Through Week 144 With Treatment-emergent Reductions in HIV Susceptibility to Abacavir, Lamivudine, Atazanavir, or Ritonavir
participantsABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
PAR with reduced abacavir susceptibility01
PAR with reduced lamivudine susceptibility11
PAR with reduced atazanavir susceptibility01
PAR with reduced ritonavir susceptibility01
SecondaryMean Percent Compliance at Week 36

Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.

Time frame:
Week 36
Reported as:
Mean · percent compliance
Mean Percent Compliance at Week 36
percent complianceABC/3TC + ATV/r: Induction Phase
Abacavir/Lamivudine92.2 ± 13.05
Ritonavir92.3 ± 12.15
Atazanavir92.7 ± 12.50
SecondaryMean Percent Compliance at Week 84

Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.

Time frame:
Week 84
Reported as:
Mean · percent compliance
Mean Percent Compliance at Week 84
percent complianceABC/3TC + ATV: Randomized PhaseABC/3TC + ATV/r: Randomized Phase
Abacavir/Lamivudine92.0 ± 11.6291.2 ± 13.49
Ritonavir92.9 ± 11.6491.5 ± 12.23
Atazanavir98.9 ± 5.3292.4 ± 11.89
SecondaryMean Percent Compliance at Week 144

Percent compliance is defined as the total number of pills taken divided by the total number of pills prescribed. The total number of pills taken was calculated by subtracting any returned pills from the total number of pills that were dispensed to each participant during this period. Compliance was calculated for each medication in the regimen.

Time frame:
Week 144
Reported as:
Mean · percent compliance
Mean Percent Compliance at Week 144
percent complianceABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
Abacavir/Lamivudine92.0 ± 12.6590.1 ± 15.35
Ritonavir93.3 ± 11.0790.1 ± 14.58
Atazanavir99.1 ± 4.5491.4 ± 13.99

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABC/3TC + ATV/r: Induction Phase—39/515 (7.6%)237/515 (46%)
ABC/3TC + ATV: Randomization Phase—22/210 (10.5%)116/210 (55.2%)
ABC/3TC + ATV/r: Randomization Phase—22/209 (10.5%)123/209 (58.9%)
ABC/3TC + ATV: Extension Phase—24/189 (12.7%)123/189 (65.1%)
ABC/3TC + ATV/r: Extension Phase—24/180 (13.3%)130/180 (72.2%)
Most frequent serious events
Showing 10 of 81
Most frequent serious events
EventABC/3TC + ATV/r: Induction PhaseABC/3TC + ATV: Randomization PhaseABC/3TC + ATV/r: Randomization PhaseABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
Drug hypersensitivityImmune system disorders5/5152/2103/2091/1894/180
CellulitisInfections and infestations1/5152/2100/2094/1890/180
AppendicitisInfections and infestations3/5152/2101/2091/1892/180
Cerebrovascular accidentNervous system disorders1/5150/2102/2090/1892/180
BronchitisInfections and infestations1/5150/2101/2092/1890/180
NauseaGastrointestinal disorders1/5151/2100/2092/1890/180
VomitingGastrointestinal disorders1/5151/2100/2092/1890/180
Non-cardiac chest painGeneral disorders0/5151/2100/2092/1890/180
Appendicitis, perforatedInfections and infestations0/5151/2101/2091/1891/180
PneumoniaInfections and infestations2/5150/2101/2091/1891/180
Most frequent other events
Showing 10 of 31
Most frequent other events
EventABC/3TC + ATV/r: Induction PhaseABC/3TC + ATV: Randomization PhaseABC/3TC + ATV/r: Randomization PhaseABC/3TC + ATV: Extension PhaseABC/3TC + ATV/r: Extension Phase
SinusitisInfections and infestations21/51515/21019/20919/18925/180
Blood bilirubin increasedHepatobiliary disorders40/51520/21022/20922/18924/180
DiarrhoeaGastrointestinal disorders42/51524/21023/20925/18921/180
BronchitisInfections and infestations18/51511/21022/20920/18922/180
HyperbilirubinaemiaHepatobiliary disorders30/51514/21020/20914/18920/180
Upper respiratory tract infectionInfections and infestations16/51513/21016/20920/18919/180
DepressionPsychiatric disorders18/51511/21010/20911/18915/180
InsomniaPsychiatric disorders17/5156/21011/20911/18913/180
NauseaGastrointestinal disorders24/51512/21010/2099/18912/180
SyphilisInfections and infestations7/5155/2107/20912/18910/180

Baseline characteristics

Age Continuous
Age Continuous(Years)ABC/3TC + ATV/r
Mean38.3 ± 10.03
Sex: Female, Male
Sex: Female, Male(Participants)ABC/3TC + ATV/r
Female86
Male429
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)ABC/3TC + ATV/r
African American/African Heritage167
American Indian or Alaskan Native9
Asian - Central/South Asian Heritage4
Asian - East Asian Heritage3
Asian - Japanese Heritage1
Asian - South East Asian Heritage3
Native Hawaiian or Other Pacific Islander1
White - Arabic/North African Heritage5
White - White/Caucasian/European Heritage316
Mixed Race6
Number of participants with the indicated baseline HIV-RNA level
Number of participants with the indicated baseline HIV-RNA level(participants)ABC/3TC + ATV/r
HIV-1 RNA <100,000227
HIV-1 RNA 100,000-<250,000143
HIV-1 RNA 250,000-<500,00073
HIV-1 RNA >=500,00072
Number of participants with the indicated Baseline CD4+ Cell Count
Number of participants with the indicated Baseline CD4+ Cell Count(participants)ABC/3TC + ATV/r
CD4+ cells <5069
CD4+ cells 50-<200190
CD4+ cells >=200256
Number of participants with the indicated Center for Disease Control (CDC) Classification
Number of participants with the indicated Center for Disease Control (CDC) Classification(participants)ABC/3TC + ATV/r
Asymptomatic HIV Infection353
Symptomatic (non-AIDS) condition97
AIDS65
Median Baseline CD4+ Cell Count
Median Baseline CD4+ Cell Count(cells per cubic millimeter)ABC/3TC + ATV/r
Median199 (19 to 754)
Median Baseline HIV-1 RNA Level
Median Baseline HIV-1 RNA Level(log10 copies/ml)ABC/3TC + ATV/r
Median5.076 (2.989 to 6.620)
09

Study locations

72 sites
  • GSK Investigational Site
    Phoenix, Arizona 85012, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90022, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Oakland, California 94609, United States
  • GSK Investigational Site
    Denver, Colorado 80220, United States
  • GSK Investigational Site
    Glastonbury, Connecticut 06033, United States
  • GSK Investigational Site
    Washington, District of Columbia 20007, United States
  • GSK Investigational Site
    Washington, District of Columbia 20009, United States
  • GSK Investigational Site
    Washington, District of Columbia 20036, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Fort Pierce, Florida 34982, United States
  • GSK Investigational Site
    Ft. Lauderdale, Florida 33306, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Plantation, Florida 33317, United States
  • GSK Investigational Site
    Sarasota, Florida 34243, United States
  • GSK Investigational Site
    Tampa, Florida 33602, United States
  • GSK Investigational Site
    Tampa, Florida 33607, United States
  • GSK Investigational Site
    Atlanta, Georgia 30308, United States
  • GSK Investigational Site
    Atlanta, Georgia 30309, United States
  • GSK Investigational Site
    Atlanta, Georgia 30339, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Chicago, Illinois 60637, United States
  • GSK Investigational Site
    Chicago, Illinois 60657, United States
  • GSK Investigational Site
    Maywood, Illinois 60153, United States
  • GSK Investigational Site
    Lexington, Kentucky 40536, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55415, United States
  • GSK Investigational Site
    St. Louis, Missouri 63110, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08844, United States
  • GSK Investigational Site
    Newark, New Jersey 07102, United States
  • GSK Investigational Site
    Somers Point, New Jersey 08244, United States
  • GSK Investigational Site
    New York, New York 10011, United States
  • GSK Investigational Site
    Valhalla, New York 10595, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Greenville, North Carolina 27834, United States
  • GSK Investigational Site
    Akron, Ohio 44304, United States
  • GSK Investigational Site
    Toledo, Ohio 43614, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19107, United States
  • GSK Investigational Site
    Providence, Rhode Island 2906, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Dallas, Texas 75204, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    El Paso, Texas 79925, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Galveston, Texas 77555, United States
  • GSK Investigational Site
    Houston, Texas 77004, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Houston, Texas 77057, United States
  • GSK Investigational Site
    Longview, Texas 75605, United States
  • GSK Investigational Site
    Annandale, Virginia 22003, United States
  • GSK Investigational Site
    Norfolk, Virginia 23507, United States
  • GSK Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5B 1L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 5B1, Canada
  • GSK Investigational Site
    Montreal, Quebec H2X 2P4, Canada
  • GSK Investigational Site
    Ponce, 00717, Puerto Rico
  • GSK Investigational Site
    Ponce, 00731, Puerto Rico
  • GSK Investigational Site
    San Juan, 00909-1711, Puerto Rico
  • GSK Investigational Site
    San Juan, 00910, Puerto Rico
10

References and documents

Publications

  • L Ross, E Dejesus, M Potter, A LaMarca, D Murphy, I Melendez-Rivera, D Ward, P Wannamaker, J Uy, L Patel, H Amrine-Madsen, J Horton. Epidemiological and Genotypic Clustering of HIV infection within North America During 2007 International HIV & Hepatitis Drug Resistance Workshop & Curative Strategies, 8-12 June 2010, Dubrovnik, Croatia, Poster 150.
  • Young B, Squires K, Patel P, Dejesus E, Bellos N, Berger D, Sutherland-Phillips DH, Liao Q, Shaefer M, Wannamaker P. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS. 2008 Aug 20;22(13):1673-5. doi: 10.1097/QAD.0b013e32830719aa. PubMed 18670229 ↗
  • • L Ross, K Squires, B Young, E DeJesus, N Bellos, D Murphy, A Rachlis, H Zhao, L Patel, L Ross, P Wannamaker, M Shaefer. Genotypic Screening Impact in ARIES [Atazanavir (ATV) + Ritonavir (/r) + Abacavir/Lamivudine (ABC/3TC) for 36 Weeks Followed By Randomization to ATV +ABC/3TC or ATV/r + ABC/3TC for 48 Wks in HIV-infected, ART Naïve Patients] :Low Rates of Virologic Failure. The 19th Annual Canadian Conference on HIV/AIDS Research, 13-16 May 2010, Saskatoon, Canada. Poster P-169.
  • K Squires, E DeJesus, N Bellos, D Ward, D Murphy, H Zhao, L Patel, L Ross, P Wannamaker, M Shaefer. Sustained Virologic Efficacy of Atazanavir (ATV) Versus Atazanavir/Ritonavir (ATV/r), each in Combination with Abacavir/Lamivudine (ABC/3TC) over 120 Weeks: the ARIES Trial. 48th ICAAC; September 12-15, 2010, Boston, MA. Poster H-204.
  • K Squires, B Young, E DeJesus, N Bellos, D Murphy, D Sutherland-Phillips, H Zhao, L Patel, L Ross, P Wannamaker, M Shaefer. Atazanavir/Ritonavir (ATV/r) + Abacavir/Lamivudine (ABC/3TC) in Antiretroviral (ART)-Naive HIV-1 Infected HLA-B*5701 Negative Subjects Demonstrates Efficacy and Safety: the ARIES Trial. 48th ICAAC; October 25-28, 2008, Washington, DC. Poster H-1250a.
  • K Squires, B Young, E DeJesus, N Bellos, D Murphy, D Sutherland-Phillips, H Zhao, L Patel, L Ross, P Wannamaker, M Shaefer. Similar Efficacy and Tolerability of Atazanavir (ATV) Compared to ATV/Ritonavir (RTV, r), Each in Combination with Abacavir/Lamivudine (ABC/3TC), after Initial Suppression with ABC/3TC + ATV/r in HIV-1 Infected Patients: 84 Week Results of the ARIES Trial. 5th IAS Conference; Cape Town, South Africa. Abstract WELBB103
  • Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES Study Team. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials. 2010 Mar-Apr;11(2):69-79. doi: 10.1310/hct1102-69. PubMed 20542844 ↗
  • Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010 Aug 24;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b. PubMed 20613461 ↗
  • Ross LL, Horton J, Hasan S, Brown JR, Murphy D, DeJesus E, Potter M, LaMarca A, Melendez-Rivera I, Ward D, Uy J, Shaefer MS. HIV-1 transmission patterns in antiretroviral therapy-naive, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing. PLoS One. 2014 Feb 26;9(2):e89611. doi: 10.1371/journal.pone.0089611. eCollection 2014. PubMed 24586911 ↗
  • Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Ward D, Zhao HH, Ross LL, Shaefer MS; ARIES Study Team. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2012 Sep-Oct;13(5):233-44. doi: 10.1310/hct1305-233. PubMed 23134624 ↗
  • Young B, Squires KE, Ross LL, Santiago L, Sloan LM, Zhao HH, Wine BC, Pakes GE, Margolis DA, Shaefer MS; Aries EPZ108859 Study Team. Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses. 2013 Feb;29(2):350-8. doi: 10.1089/aid.2012.0278. Epub 2012 Dec 5. PubMed 23039030 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 1 month after primary completion. A results delay was requested in May 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2007
First posted
Feb 27, 2007
Start
Mar 2007
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results delay requested
May 14, 2010
Results first posted
Aug 17, 2011
Last update
Mar 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00440947
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 27, 2007
Start date
Mar 2007
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Aug 17, 2011
Last update
Mar 22, 2012

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abacavir · Lamivudine · Atazanavir · Ritonavir

Start the discussion